ArticleMolecules (Basel, Switzerland)2022
Development and Optimization of Ciprofloxacin HCl-Loaded Chitosan Nanoparticles Using Box-Behnken Experimental Design.
Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 31 citations in OpenAlex.
- A Box-Behnken-Optimized Phytosomal Strategy for Diosgenin: Enhancing Oral Delivery and Antipsoriatic Efficacy in a Preclinical Model.ACS omega · 2026Article
- Optimized Chitosan Nanoparticles for Enhanced Ciprofloxacin Delivery and Activity Against Resistant Bacteria.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Process Optimization of Novel Boronophenylalanine Liposomes Through Box-Behnken Response Surface Design and Preliminary Evaluation in A549 Lung Carcinoma Cells for Boron Neutron Capture Therapy.Molecules (Basel, Switzerland) · 2026Article
- Enhanced Antimicrobial Activity of Ciprofloxacin Encapsulated in Sophorolipid-Based Nano-Assemblies Against Ciprofloxacin-/Methicillin-ResistantPharmaceutics · 2026Article
- Investigation of Anti-Cancer Properties of Nano-Encapsulated Ciprofloxacin Using 3D Cancer Cell Spheroids as Tumour Models.International journal of molecular sciences · 2025Article
- Formulation and characterization of mangosteen rind extract nanocapsules as a feed additive candidate of poultry.Open veterinary journal · 2025Article
- Review
- TPGS-modified Chitosan Nanoparticles of EGFR Inhibitor: Physicochemical andCurrent drug delivery · 2025Article
- A Novel Delivery System for the Combined Use of Natural Ingredients: The Preparation of Berberine Hydrochloride-Matrine Liposomes and Preliminary Exploration of Their Anti-Tumor Activity.Molecules (Basel, Switzerland) · 2024Article
- Article
- Article
- Development of Chincho (Gels (Basel, Switzerland) · 2022Article
- Role of Nanotechnology in Overcoming the Multidrug Resistance in Cancer Therapy: A Review.Molecules (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Various chitosan (CS)-based nanoparticles (CS-NPs) of ciprofloxacin hydrochloride (CHCl) have been investigated for therapeutic delivery and to enhance antimicrobial efficacy. However, the Box-Behnken design (BBD)-supported statistical optimization of NPs of CHCl has not been performed in the literature. As a result, the goal of this study was to look into the key interactions and quadratic impacts of formulation variables on the performance of CHCl-CS-NPs in a systematic way. To optimize CHCl-loaded CS-NPs generated by the ionic gelation process, the response surface methodology (RSM) was used. The BBD was used with three factors on three levels and three replicas at the central point. Tripolyphosphate, CS concentrations, and ultrasonication energy were chosen as independent variables after preliminary screening. Particle size (PS), polydispersity index (PDI), zeta potential (ZP), encapsulation efficiency (EE), and in vitro release were the dependent factors (responses). Prepared NPs were found in the PS range of 198-304 nm with a ZP of 27-42 mV. EE and drug release were in the range of 23-45% and 36-61%, respectively. All of the responses were optimized at the same time using a desirability function based on Design Expert
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.